The original landmark study on the use of tissue plasminogen activator (TPA, specifically alteplase) for ischemic stroke that was published in the The New England Journal of Medicine in 1995 by The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA study group[2–7] demonstrated that there was no immediate improvement in patient outcomes. This evidence concerns the gene PLAT and stroke disorder.